证券代码：688076 证券简称：ST诺泰 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 二、上年同期业绩情况 2024年度，公司利润总额：43,850.42万元；归属于母公司所有者的净利润：40,439.00万元；归属于母公 司所有者的扣除非经常性损益的净利润：40,782.21万元；基本每股收益：1.88元/股。 三、本期业绩变化的主要原因 （一）报告期内，公司整体销售收入增长，但受行业价格波动影响及公司固定成本增加，导致公司毛利 率水平同比有所下降。 （二）报告期内，公司根据《企业会计准则》等有关要求，对相关资产进行减值测试后，对部分资产计 提减值准备，对公司本期业绩产生影响。 （二）业绩预告情况 （1）经财务部门初步测算，公司预计2025年年度实现营业收入人民币190,000万元到200,000万元，与上 年同期（法定披露数据）相比，将增加27,519.81万元到37,519.81万元，同比增加16 ...

Core Viewpoint - The company anticipates a significant increase in losses for the fiscal year 2025 compared to the previous year, with projected net losses ranging from 29.4 million to 44 million yuan [2][4]. Financial Performance Forecast - The estimated net profit attributable to the parent company for 2025 is projected to be between -29.4 million and -44 million yuan, representing an increase in losses of 27.4 million to 41.99 million yuan compared to the previous year [2][4]. - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -81.9 million and -122.8 million yuan, indicating an increase in losses of 10.06 million to 50.96 million yuan compared to the previous year [2][4]. Previous Year Performance - In 2024, the company reported a total profit of 4.1872 million yuan, with a net loss attributable to the parent company of -200.17 million yuan. The net profit excluding non-recurring gains and losses was -71.8371 million yuan [6]. Reasons for Performance Changes - The increase in losses is attributed to intensified industry competition and ongoing medical procurement policies, which have led to a decrease in revenue from self-produced diagnostic test products due to a VAT adjustment to 13% [7]. - The company has made efforts to reduce long-term accounts receivable, resulting in a decrease in the balance of such receivables [7]. - The company has recognized impairment provisions for various assets based on prudence principles, in accordance with accounting standards [7]. - There has been a reduction in government subsidies received during the reporting period [8]. - Despite a decrease in R&D spending, the company maintains a relatively high intensity of R&D investment, focusing on core product lines and enhancing overall solution capabilities [9].

（1）经科兴生物制药股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属 于母公司所有者的净利润为13,500万元至17,500万元，与上年同期（法定披露数据）相比，将增加 10,352万元至14,352万元，同比增加328.83%至455.89%。 （2）预计归属于母公司所有者的扣除非经常性损益的净利润为5,000万元至7,000万元，与上年同期（法 定披露数据）相比，将增加1,475万元至3,475万元，同比增加41.83%至98.56%。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 证券代码：688136 证券简称：科兴制药 公告编号：2026-009 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 除此之外，公司不存在其他影响本次业绩预告内容准确性的重大不确定因素。 五、其他说明事项 以上预告数据仅为初步核算数据，具体准确的财务数据以公司正式披露的经审计后的 ...

Performance Forecast - The company expects a net profit loss for the period from January 1, 2025, to December 31, 2025, with an estimated loss of approximately 110 million to 150 million yuan [1] - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by the accounting firm [1] Reasons for Performance Changes - The company is optimizing its business structure, which is expected to impact short-term performance. The focus is on increasing sales gross margin, ensuring asset safety, improving financing channels, and optimizing capital returns [1] - The company is evaluating long-term loss-making subsidiaries or business segments and plans to divest poor-performing assets through methods such as equity transfer, asset sales, and liquidation. This is expected to impact the net profit loss by approximately 110 million to 150 million yuan [1] Asset Impairment and Credit Losses - The company anticipates goodwill impairment of approximately 120 million to 150 million yuan, which is a significant decrease compared to previous periods, thus reducing the impact on current performance [2] - Credit impairment losses are expected to be around 150 million to 220 million yuan, with improvements in credit management and collection efforts. However, some public medical institutions have long-standing debt recovery issues that may exert pressure on overall credit impairment risk [2]

Core Viewpoint - The company anticipates a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of between RMB 270 million and RMB 320 million, representing a year-on-year increase of 54.93% to 83.63% [2] Performance Forecast - The expected net profit attributable to shareholders for 2025 is between RMB 270 million and RMB 320 million, an increase of RMB 95.73 million to RMB 145.73 million compared to the previous year [2] - The projected net profit, excluding non-recurring gains and losses, is between RMB 167 million and RMB 217 million, reflecting an increase of RMB 59.73 million to RMB 109.73 million year-on-year [2] Previous Year Performance - In the previous year, the total profit was RMB 213.39 million, with a net profit attributable to shareholders of RMB 174.27 million, and a net profit excluding non-recurring gains and losses of RMB 107.27 million [2] Reasons for Performance Changes - The company is focusing on "agile management and growth efficiency," optimizing its organizational structure and operational model, which is expected to enhance operational efficiency and reduce costs, leading to a projected net profit increase of 54.93% to 83.63% [2][3] - Management expenses are expected to decrease by over 10% year-on-year due to effective cost control [3] - Sales expenses are projected to decline by over 30% year-on-year, contributing to improved profitability despite revenue pressures [3] Research and Innovation - The company is advancing research in key areas such as glycoscience and cell biology, focusing on the regulation mechanisms of extracellular matrix and aging intervention [3] - The integration of AI technology into business processes is expected to enhance operational efficiency across production, supply chain, and management [3] Future Outlook - The company will continue to prioritize technological innovation to strengthen its long-term competitive advantage and improve operational quality and sustainable development [4]

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -85 million yuan and -66 million yuan [2] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -84 million yuan and -65 million yuan [3] - The financial data in this performance forecast has not been audited by a registered accountant [4] Group 2 - In the same period last year, the total profit was -54.2183 million yuan, with a net profit attributable to shareholders of the parent company at -54.4163 million yuan, and a net profit after deducting non-recurring gains and losses at -71.7486 million yuan [5] - The earnings per share for the previous year was -0.78 yuan per share [6] Group 3 - The main reasons for the performance changes include an increase in revenue from the main business due to the continuous enrichment of the product line and the development of new business [6] - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages [6] - The company has expanded its marketing team and enhanced brand marketing efforts, leading to an increase in sales expenses [6] - A reduction in government subsidies compared to the previous year has been noted, impacting other income [7]

荣昌生物制药（烟台）股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 证券代码：688331 证券简称：荣昌生物 公告编号：2026-006 港股代码：09995 港股简称：榮昌生物 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经荣昌生物制药（烟台）股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年度营 业收入约325,000万元，与上年同期相比，将增加收入约153,314万元，同比增加约89%。 （2）公司预计2025年度实现归属于母公司所有者的净利润约71,600万元，与上年同期相比，实现扭亏 为盈。 （3）公司预计2025年度归属于母公司所有者扣除非经常性损益后的净利润约7,850万元，与上年同期相 比，实现扭亏为盈。 （三）本期业绩预告相关的财务数据未经注册会计师预审计。 二、上年同期业绩情况 2024年度营业收入171,686.17万元。 2024年度归属于母公司所有者扣除非经常性损益后的净亏损1 ...

Core Viewpoint - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. forecasts a revenue increase for 2025, while also projecting a higher net loss compared to the previous year, primarily due to the absence of investment gains from subsidiary disposals in 2024 [2][5]. Group 1: Performance Forecast - The company expects to achieve an operating revenue of approximately CNY 140 million to CNY 145 million in 2025, representing a year-on-year increase of 8.13% to 11.99% [2][5]. - The projected net loss attributable to shareholders is estimated to be between CNY 255 million and CNY 290 million, an increase in loss of approximately CNY 53.62 million to CNY 88.62 million compared to 2024 [2][5]. - The net loss excluding non-recurring gains and losses is expected to be between CNY 288 million and CNY 323 million, a reduction in loss of approximately CNY 4.31 million to CNY 39.31 million, mainly due to revenue growth and reduced expenses [2][5]. Group 2: Revenue Sources - Revenue is primarily derived from the sales of the innovative anti-HIV drug Aikening (generic name: Aibowei Tai), the agency product Viread (Tenofovir), and the newly approved far-infrared therapeutic patch (Xiaoyan Yipai) [2][5]. - The sales of Aikening are focused on the inpatient market, with continued growth in outpatient revenue, supported by its reputation as a preferred medication for hospitalized patients [5][6]. Group 3: R&D and Commercialization Progress - The company is focusing on the research and development of small nucleic acid drugs and has submitted IND applications for several candidates, including FB7013 and FB7011, which are in various stages of clinical development [7][8]. - The company has completed nationwide sales registration for the agency product Viread and has initiated commercial promotion for the far-infrared therapeutic patch [6][8]. - R&D expenses are projected to be between CNY 138 million and CNY 145 million, reflecting a year-on-year increase of 0.58% to 5.68%, as the company emphasizes early-stage development of new drugs [5][7].

Core Viewpoint - The company, Borui Biopharmaceuticals, anticipates a significant decline in its 2025 annual net profit, projecting a decrease of 67.28% to 78.17% compared to the previous year, primarily due to changes in market demand and increased R&D expenses [1][4]. Financial Performance Forecast - The estimated net profit attributable to the parent company for 2025 is projected to be between 41.3 million and 61.9 million yuan, representing a year-on-year decrease of 67.28% to 78.17% [1]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 4.3 million and 24.9 million yuan, reflecting a year-on-year decrease of 86.21% to 97.62% [1]. Previous Year Performance - In the previous year, the total profit was 157.2 million yuan, with a net profit attributable to the parent company of 189.2 million yuan, and a net profit after deducting non-recurring gains and losses of 180.5 million yuan [2]. Reasons for Performance Changes - The anticipated decline in net profit is attributed to several factors, including changes in flu trends, shifts in competitive landscape, fluctuations in customer demand, reduced operating income, increased depreciation from completed construction projects, and higher R&D expenses due to intensified investment in innovative drugs [4]. - The company is focusing on the metabolic field and has developed a competitive product pipeline in multi-target combination therapies and innovative dosing frequencies to provide comprehensive and personalized treatment options for patients [4]. Research and Development Progress - The company has made significant progress in its research projects, including: 1. BGM0504 injection for type 2 diabetes and weight loss, currently in Phase III clinical trials in China and undergoing regulatory processes in the U.S. and Indonesia [4]. 2. Oral BGM0504 tablets, with IND applications approved in both China and the U.S., currently in Phase I clinical studies [5]. 3. BGM1812 injection, a new long-acting Amylin analog, with ongoing Phase I clinical trials in both China and the U.S. [6]. 4. Oral BGM1812, in preclinical research, utilizing an authorized oral peptide formulation platform [7]. 5. BGM1962, a novel long-acting selective amylin receptor agonist, currently in preclinical research [8]. 6. MSTN cyclic peptide injection, aimed at weight management, currently in preclinical candidate stage [9]. 7. ALK7-targeted siRNA project, also in preclinical candidate stage, intended for obesity treatment [10].

Core Viewpoint - The company, Changchun High-tech (SZ000661), has issued a shocking earnings forecast for 2025, predicting a significant decline in net profit compared to the previous year, primarily due to increased R&D expenses, adjustments in sales strategies following the inclusion of long-acting growth hormone products in the national medical insurance catalog, and losses from its subsidiary [2][3]. Group 1: Earnings Forecast - For 2025, the company expects a net profit attributable to shareholders between 150 million to 220 million yuan, a drastic decrease of 91.48% to 94.19% from 2.583 billion yuan in 2024 [2]. - The forecasted net profit excluding non-recurring items for 2025 is estimated to be between 437 million to 507 million yuan, down 82.09% to 84.56% from 2.830 billion yuan in the previous year [2]. Group 2: Reasons for Profit Decline - The decline in profit is attributed to multiple factors, including increased R&D expenses as several products enter clinical stages and higher sales expenses for promoting new products [3]. - The company adjusted its sales strategies and pricing for long-acting growth hormone products after they were included in the national medical insurance catalog, which negatively impacted revenue and profit [3]. - Losses from the subsidiary, Changchun Baike Biotechnology Co., further contributed to the overall decline in performance [3]. Group 3: Market Position and Challenges - The company holds a 100% market share in the pegylated recombinant human growth hormone injection and a 68.4% market share in short-acting growth hormone products, indicating a strong competitive position [4]. - However, starting in 2024, the company began experiencing a downward trend in performance, with revenues and net profits decreasing by 7.55% and 43.01%, respectively, in 2024 [5]. - The introduction of price reductions for growth hormones in 2025 is expected to exert additional pressure on revenue growth [5]. Group 4: Strategic Initiatives - The company is increasing its R&D investment, which rose by 23% to 1.733 billion yuan in the first three quarters of 2025, representing 17.68% of total revenue [5]. - A recent business development transaction with Yarrow Bioscience, Inc. is expected to yield significant future payments, although these revenues will not be recognized in the 2025 financial statements [6]. - The company is also focusing on expanding its overseas market presence and has submitted an application for listing on the Hong Kong Stock Exchange to support this initiative [6].